In January 2004, tiotropium bromide (Spiriva; Boehringer Ingelheim/Pfizer), an orally inhaled anticholinergic drug, was approved by the US FDA for the treatment of chronic obstructive pulmonary ...
In addition to the new exacerbation data, the indication for Stiolto Respimat has been revised. The Food and Drug Administration (FDA) has approved updated labeling for Stiolto Respimat (tiotropium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback